Channelchek - Looking for the next apple? This is the orchard.

ZOMDF

$0.08

(-0.88%)

FLWS

$4.04

(3.06%)

ACCO

$4.17

(4.91%)

ARLP

$24.75

(0.73%)

AUIAF

$0.15

(0%)

AZZ

$150.41

(-0.03%)

BTBT

$1.48

(-6.33%)

BTM

$0.49

(0%)

CVKD

$2.37

(0.85%)

LCE:CA

$0.24

(-4%)

COCP

$0.96

(-0.5%)

CDRO

$9.56

(-0.26%)

CVGI

$4.69

(-2.09%)

LODE

$3.96

(-4.69%)

CMTL

$1.67

(-4.86%)

CNDT

$1.6

(5.59%)

CXW

$30.92

(-0.55%)

CMLS

$0.01

(0%)

DRCT

$2.46

(-4.65%)

DLHC

$5.55

(3.16%)

SSP

$3.13

(1.13%)

ELDN

$3.92

(-2.36%)

EVC

$10.44

(-5.69%)

EDRY

$22.84

(-0.65%)

ESEA

$72.31

(1.2%)

FAT

$0.16

(0%)

RAIL

$7.9

(-0.75%)

GDEV

$11.7

(0%)

GOVX

$0.87

(-14.29%)

GOCO

$0.3

(0%)

GHM

$108.87

(-1.21%)

GLDD

$17

(0%)

GYRE

$7.58

(-1.88%)

HMENF

$1.85

(-2.12%)

III

$4.09

(3.02%)

IPOOF

$10.64

(-0.19%)

KELYA

$15.47

(7.96%)

KTOS

$47.1

(-5.19%)

LUCK

$7.2

(0.14%)

MAIA

$1.36

(-7.14%)

MGROF

$0.26

(0%)

NTRB

$3.04

(-0.33%)

OCGN

$1.36

(-4.55%)

PERF

$1.93

(0.52%)

QMCI

$0.15

(0%)

RGP

$4.84

(5.56%)

SGA

$9.25

(-0.14%)

SHWZ

(0%)

SHIP

$14.81

(-2.76%)

SLQT

$0.74

(-1.56%)

SKYX

$1.21

(-3.52%)

SNAL

$5.07

(2.01%)

GEO

$29.67

(-0.5%)

ODP

$28

(0%)

TNXP

$11.35

(-2.24%)

TSQ

$6.79

(0.07%)

TZOO

$10.96

(-1.13%)

UNCY

$5.02

(0%)

VVX

$75.8

(0.2%)

VNCE

$6.25

(1.46%)

XELB

$1.44

(-2.38%)

ZOMDF

$0.08

(-0.88%)

FLWS

$4.04

(3.06%)

channelchek-in

‌

7/16/2026

Eli Lilly Pays $3.8 Billion for AtaiBeckley as Big Pharma’s Push Into Mental Health Enters a New Phase

The pharmaceutical industry’s appetite for neuroscience innovation just produced one of the most significant mental health deals in years. Eli Lilly (NYSE: LLY) announced Wednesday it has entered into a definitive agreement to acquire AtaiBeckley (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing rapid-acting therapies for treatment-resistant depression and other serious mental health conditions. The deal values AtaiBeckley at approximately $2.8 billion in upfront equity consideration, with an additional $1.0 billion in potential milestone-based contingent value rights, bringing the total potential transaction value to approximately $3.8 billion.

3 min read